Vendor Intelligence Report: Huaian Dinglin Trading

Executive summary

Huaian Dinglin Trading’s lab record is mixed, not uniformly failing. Across 10 Finnrick lab tests, Huaian Dinglin Trading has 6 pass / 4 fail — an overall pass rate of 60%. The tested catalog is small and sharply split: Retatrutide is the comparatively stronger peptide, while Tesamorelin is fail-heavy enough that buyers should prefer a better-tested source unless they have fresh lot-specific verification. Even the stronger side carries a dose-consistency warning, and ratings become less forgiving under stricter fill and purity views.

The non-lab evidence raises channel and continuity problems. The active Peptides-US domain sits behind GoDaddy registration privacy and was moved from Cloudflare to GoDaddy nameservers shortly before the update; Peptides-US and two technically linked sister storefronts were unreachable while the Shop910 platform itself still loaded. That pattern points to disruption at the domain or tenant layer, not a simple expired-domain story.

Corporate presentation remains unresolved. A Global Sources profile contains the vendor’s own history conflict: a long-running peptide-manufacturer headline beside a much newer establishment field, with Mrs. Guoli Pei as the only named contact and no accessible Chinese registration number recovered in public sources. Storefront captures also show FDA, ISO, Trade Assurance and 99% purity-style claims without the certificate trail needed to verify scope, lot, or audited entity. The public record gives a credible direction of concern; the full report carries the artifacts that resolve how the pieces connect.

Inside the full report:

• Appendix A laboratory data with per-product pass/fail records and methodology-divergence charts for both tested peptides
• RDAP timeline of the Cloudflare-to-GoDaddy nameserver change and storefront outage
• Global Sources profile and contact-page exhibits preserving the history-claim contradiction and Guoli Pei listing
• Shop910 privacy-policy redirect capture plus shared JavaScript and Cloudflare R2 tenant indicators across peptides-us.com, lilipeptide.com, and mai-peptides.com
• Compliance-claim review covering FDA, ISO, Trade Assurance, COA-image, and 99% purity presentations
• Buyer-risk matrix and channel-verification checklist for avoiding substitute domains and private-chat reroutes

Risk assessment

• Misleading corporate and regulatory-claim risk — high: Global Sources lists Year Established: 2025 while the same profile claims 16+ years; FDA/ISO/Trade Assurance logos lack verifiable certificate details.
• Cloaking/disposable-storefront infrastructure risk — high: peptides-us.com exposed a Shop910 backend; Shop910 advertises AB-jump/cloak features and the site shares tenant-style infrastructure with related peptide storefronts.
• Tesamorelin quality risk — high: Tesamorelin has 4 Finnrick tests with 1 pass / 3 fail and a 42.26% rating, making it the weak tested product from this vendor.
• Retatrutide fill-accuracy risk — medium: Retatrutide is stronger at 80.6% with 5 pass / 1 fail, but field lab records include a 10 mg vial containing 4.39 mg (-56.1%).
• Brand-authentication and related-storefront risk — medium: No official-channel list, verified social account, certificate verifier, or authorized-reseller list was found while lilipeptide.com and mai-peptides.com share code/R2 tenant indicators.
• Infrastructure disruption and order-continuity risk — medium: As of Jul 2, 2026, peptides-us.com, lilipeptide.com, and mai-peptides.com were unreachable after a Jun 29 nameserver migration; order routing and continuity are unclear.